Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939 · see citing works

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · see citing works

Papillary and Follicular Thyroid Carcinoma

Schlumberger, M. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380506 · Cited by 1,619 · see citing works

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

Abramson, V. G., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 674 · see citing works

Herceptin acts as an anti-angiogenic cocktail

Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623 · see citing works

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E. J., Kim, S., Bycott, P. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 622 · see citing works

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569 · see citing works

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M. A., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 540 · see citing works

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Carlomagno, F., Anaganti, S., Guida, T., Salvatore, G., Troncone, G., Wilhelm, S. M., & Santoro, M. M. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj069 · Cited by 475 · see citing works

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · see citing works

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 413 · see citing works

AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts

Polverino, A. J., Coxon, A., Starnes, C. O., Diaz, Z., DeMelfi, T. M., Wang, L., BREADY, J. V., Estrada, J., Cattley, R. C., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 286 · see citing works

An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases

Kim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279 · see citing works

Prevalence ofRET/PTCRearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity

Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M., & Nikiforov, Y. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1006 · Cited by 207 · see citing works

Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.

Mazzaferri, E. L., & Massoll, N. A. (2002) · Endocrine Related Cancer · doi:10.1677/erc.0.0090227 · Cited by 182 · see citing works

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

Fagin, J. A. (2004) · Journal of Endocrinology · doi:10.1677/joe.1.05895 · Cited by 154 · see citing works

Interferon-γ-Inducible α-Chemokine CXCL10 Involvement in Graves’ Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor-γ Agonists

Antonelli, A., Rotondi, M., Ferrari, S. M., Fallahi, P., Romagnani, P., Franceschini, S. S., Serio, M., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1689 · Cited by 148 · see citing works

ZD6474 Suppresses Oncogenic RET Isoforms in a Drosophila Model for Type 2 Multiple Endocrine Neoplasia Syndromes and Papillary Thyroid Carcinoma

Vidal, M., Wells, S. A., Ryan, A. J., & Cagan, R. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4561 · Cited by 139 · see citing works

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A., Gazit, A., Levitzki, A., & Santoro, M. M. (2002) · PubMed · Cited by 135 · see citing works

The interaction of Thrombospondins with extracellular matrix proteins

Tan, K., & Lawler, J. (2009) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0074-2 · Cited by 129 · see citing works

Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level

Zhang, X., Kazerounian, S., Duquette, M. A., Perruzzi, C. A., Nagy, J. A., Dvorak, H. F., Parangi, S., & Lawler, J. (2009) · The FASEB Journal · doi:10.1096/fj.09-131649 · Cited by 119 · see citing works

Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2)

Carlomagno, F., Vitagliano, D., Guida, T., Basolo, F., Castellone, M. D., Melillo, R. M., Fusco, A., & Santoro, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021278 · Cited by 113 · see citing works

Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments

Mirochnik, Y., Kwiatek, A. M., & Volpert, O. V. (2008) · Current Drug Targets · doi:10.2174/138945008785909347 · Cited by 108 · see citing works

Dedifferentiated thyroid cancer: A therapeutic challenge

Antonelli, A., Fallahi, P., Ferrari, S. M., Carpi, A., Berti, P., Materazzi, G., Minuto, M. N., Guastalli, M., & Miccoli, P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.07.056 · Cited by 99 · see citing works

Methods and goals for the use of in vitro and in vivo chemosensitivity testing

Blumenthal, R. D., & Goldenberg, D. M. (2007) · Molecular Biotechnology · doi:10.1007/bf02686104 · Cited by 75 · see citing works

Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists

Antonelli, A., Ferrari, S. M., Fallahi, P., Frascerra, S., Piaggi, S., Gelmini, S., Lupi, C., Minuto, M. N., Berti, P., Benvenga, S., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0337 · Cited by 73 · see citing works

Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

Antonelli, A., Ferrari, S. M., Fallahi, P., Berti, P., Materazzi, G., Minuto, M. N., Giannini, R., Marchetti, I., Barani, L., Basolo, F., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03415.x · Cited by 71 · see citing works

Primary cell cultures from anaplastic thyroid cancer obtained by fine‐needle aspiration used for chemosensitivity tests

Antonelli, A., Ferrari, S. M., Fallahi, P., Berti, P., Materazzi, G., Barani, L., Marchetti, I., Ferrannini, E., & Miccoli, P. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03182.x · Cited by 67 · see citing works

Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration

Antonelli, A., Ferrari, S. M., Fallahi, P., Berti, P., Materazzi, G., Marchetti, I., Ugolini, C., Basolo, F., Miccoli, P., & Ferrannini, E. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0190 · Cited by 62 · see citing works

Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo

Celano, M., Schenone, S., Cosco, D., Navarra, M., Puxeddu, E., Racanicchi, L., Brullo, C., Varano, E., Alcaro, S., Ferretti, E., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0243 · Cited by 61 · see citing works

The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors

Ye, L., Santarpia, L., & Gagel, R. F. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0031 · Cited by 60 · see citing works

Second-generation kinase inhibitors

Klebl, B., & Müller, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.975 · Cited by 58 · see citing works

Inhibition of RET tyrosine kinase by SU5416

Mologni, L., Sala, E., Cazzaniga, S., Rostagno, R., Kuoni, T., Puttini, M., Bain, J., Cleris, L., Redaelli, S., Riva, B., et al. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01999 · Cited by 55 · see citing works

Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics

Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00022-3 · Cited by 52 · see citing works

NovelN2-Substituted Pyrazolo[3,4-d]pyrimidine Adenosine A3Receptor Antagonists: Inhibition of A3-Mediated Human Glioblastoma Cell Proliferation†

Taliani, S., Motta, C. L., Mugnaini, L., Simorini, F., Salerno, S., Marini, A. M., Settimo, F. D., Cosconati, S., Cosimelli, B., Greco, G., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901785w · Cited by 50 · see citing works

Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1

Lanzi, C., Cassinelli, G., Cuccuru, G., Zaffaroni, N., Supino, R., Vignati, S., Zanchi, C., Yamamoto, M., & Zunino, F. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2381-8 · Cited by 45 · see citing works

Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates

Morisi, R., Celano, M., Tosi, E., Schenone, S., Navarra, M., Ferretti, E., Costante, G., Durante, C., Botta, G., D’Agostino, M., et al. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03349220 · Cited by 43 · see citing works

Construction and Validation of a RET TK Catalytic Domain by Homology Modeling

Tuccinardi, T., Manetti, F., Schenone, S., Martinelli, A., & Botta, M. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci6004383 · Cited by 38 · see citing works

New Targeted Molecular Therapies for Dedifferentiated Thyroid Cancer

Antonelli, A., Ferri, C., Ferrari, S. M., Sebastiani, M., Colaci, M., Ruffilli, I., & Fallahi, P. (2010) · Journal of Oncology · doi:10.1155/2010/921682 · Cited by 36 · see citing works

Establishment of xenografts and cell lines from well-differentiated human thyroid carcinoma

Lin, J., Chao, T., Weng, H., Huang, H.-S., & Ho, Y. (1996) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199610)63:2 · Cited by 30 · see citing works

Adjuvant therapy and long-term management of differentiated thyroid carcinoma

Sherman, S. I. (1999) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199901/02)16:1 · Cited by 4 · see citing works

Autoimmune thyroid disorders

Antonelli, A., Ferrari, S. M., Corrado, A., Domenicantonio, A. D., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.10.016 · Cited by 951 · see citing works

Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases

Antonelli, A., Ferrari, S. M., Giuggioli, D., Ferrannini, E., Ferri, C., & Fallahi, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.10.010 · Cited by 595 · see citing works

Thyroid autoimmune disorders and cancer

Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Paparo, S. R., & Antonelli, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.019 · Cited by 181 · see citing works

Biologically Driven Synthesis of Pyrazolo[3,4-d]pyrimidines As Protein Kinase Inhibitors: An Old Scaffold As a New Tool for Medicinal Chemistry and Chemical Biology Studies

Schenone, S., Radi, M., Musumeci, F., Brullo, C., & Botta, M. (2014) · Chemical Reviews · doi:10.1021/cr400270z · Cited by 148 · see citing works

HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer

Ferri, C. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.327 · Cited by 148 · see citing works

Development And Strategies Of VEGFR-2/KDR Inhibitors

Huang, L., Huang, Z., Bai, Z., Xie, R., Sun, L., & Lin, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.121 · Cited by 103 · see citing works

Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse

Charles, R., Iezza, G., Amendola, E., Dankort, D. L., & McMahon, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4463 · Cited by 99 · see citing works

Sunitinib in the Treatment of Thyroid Cancer

Ferrari, S. M., Centanni, M., Virili, C., Miccoli, M., Ferrari, P., Ruffilli, I., Ragusa, F., Antonelli, A., & Fallahi, P. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666171006165942 · Cited by 90 · see citing works

Molecular Targeted Therapies of Aggressive Thyroid Cancer

Ferrari, S. M., Fallahi, P., Politti, U., Materazzi, G., Baldini, E., Ulisse, S., Miccoli, P., & Antonelli, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00176 · Cited by 68 · see citing works

CXCL10 in psoriasis

Ferrari, S. M., Ruffilli, I., Colaci, M., Antonelli, A., Ferri, C., & Fallahi, P. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.07.011 · Cited by 65 · see citing works

Thyroid dysfunctions induced by tyrosine kinase inhibitors

Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.913021 · Cited by 60 · see citing works

Sorafenib and Thyroid Cancer

Fallahi, P., Ferrari, S., Santini, F., Corrado, A., Materazzi, G., Ulisse, S., Miccoli, P., & Antonelli, A. (2013) · BioDrugs · doi:10.1007/s40259-013-0049-y · Cited by 60 · see citing works

New therapies for dedifferentiated papillary thyroid cancer

Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works

CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo

Antonelli, A., Bocci, G., Motta, C. L., Ferrari, S. M., Fallahi, P., Ruffilli, I., Domenicantonio, A. D., Fioravanti, A., Sartini, S., Minuto, M. N., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1987 · Cited by 57 · see citing works

New Targeted Therapies for Thyroid Cancer

Antonelli, A., Fallahi, P., Ferrari, S. M., Ruffilli, I., Santini, F., Minuto, M. N., Galleri, D., & Miccoli, P. (2011) · Current Genomics · doi:10.2174/138920211798120808 · Cited by 53 · see citing works

CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo

Antonelli, A., Bocci, G., Fallahi, P., Motta, C. L., Ferrari, S. M., Mancusi, C., Fioravanti, A., Desidero, T. D., Sartini, S., Corti, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2321 · Cited by 51 · see citing works

Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells

Radi, M., Brullo, C., Crespan, E., Tintori, C., Musumeci, F., Biava, M., Schenone, S., Dreassi, E., Zamperini, C., Maga, G., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.079 · Cited by 47 · see citing works

RET TKI: Potential Role in Thyroid Cancers

Antonelli, A., Fallahi, P., Ferrari, S. M., Mancusi, C., Colaci, M., Santarpia, L., & Ferri, C. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0217-0 · Cited by 44 · see citing works

Cabozantinib in Thyroid Cancer

Fallahi, P., Ferrari, S. M., Bari, F. D., Materazzi, G., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892810666150708110816 · Cited by 42 · see citing works

Cytokines and HCV-related autoimmune disorders

Antonelli, A., Ferrari, S. M., Ruffilli, I., & Fallahi, P. (2014) · Immunologic Research · doi:10.1007/s12026-014-8569-1 · Cited by 40 · see citing works

Sorafenib and thyroid cancer

Park, C. H., Perini, J., Farmer, R. W., Fancy, T., Monga, M., & Remick, S. C. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.960391 · Cited by 37 · see citing works

Selective use of vandetanib in the treatment of thyroid cancer

Antonelli, A., Fallahi, P., Bari, F. D., Ferrari, S. M., Spisni, R., Materazzi, G., Miccoli, P., & Benvenga, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s72495 · Cited by 36 · see citing works

Role of glial cell line-derived neurotrophic factor in perineural invasion of pancreatic cancer

Liu, H., Li, X., Xu, Q., Lv, S., Li, J., & Ma, Q. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.03.010 · Cited by 36 · see citing works

CXCL9 chemokine in ulcerative colitis.

Elia, G., & Guglielmi, G. (2018) · PubMed · doi:10.7417/ct.2018.2085 · Cited by 34 · see citing works

Novel therapeutic clues in thyroid carcinomas: The role of targeting cancer stem cells

Antonelli, A., & Motta, C. L. (2017) · Medicinal Research Reviews · doi:10.1002/med.21448 · Cited by 33 · see citing works

Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer

Antonelli, A., Ferrari, S. M., Fallahi, P., Piaggi, S., Domenicantonio, A. D., Galleri, D., Santarpia, L., Basolo, F., Ferrannini, E., & Miccoli, P. (2012) · Cytokine · doi:10.1016/j.cyto.2012.04.042 · Cited by 32 · see citing works

Autoimmune and Neoplastic Thyroid Diseases Associated with Hepatitis C Chronic Infection

Fallahi, P., Ferrari, S. M., Politti, U., Giuggioli, D., Ferri, C., & Antonelli, A. (2014) · International Journal of Endocrinology · doi:10.1155/2014/935131 · Cited by 31 · see citing works

Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells

Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29 · see citing works

Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin

Fallahi, P., Ferrari, S. M., Elia, G., Ragusa, F., Patrizio, A., Paparo, S. R., Marone, G., Galdiero, M. R., Guglielmi, G., Foddis, R., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.013 · Cited by 27 · see citing works

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration

Ferrari, S. M., Motta, C. L., Elia, G., Ragusa, F., Ruffilli, I., Quattrini, L., Paparo, S. R., Piaggi, S., Patrizio, A., Ulisse, S., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00764 · Cited by 27 · see citing works

Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer

Benvenga, S., & Koch, C. A. (2014) · Current Genomics · doi:10.2174/1389202915999140404100958 · Cited by 26 · see citing works

Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells

Bocci, G., Fioravanti, A., Motta, C. L., Orlandi, P., Canu, B., Desidero, T. D., Mugnaini, L., Sartini, S., Cosconati, S., Frati, R., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.022 · Cited by 26 · see citing works

Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics

Jin, Y., Liu, M., Sa, R., Fu, H., Cheng, L., & Chen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.017 · Cited by 24 · see citing works

RET kinase inhibitors: a review of recent patents (2012–2015)

Mologni, L., Gambacorti-Passerini, C. B., Goekjian, P. G., & Scapozza, L. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1238073 · Cited by 23 · see citing works

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma

Nava, C. F., Scheffel, R. S., de Cristo, A. P., Ferreira, C. V., Weber, S. S., Zanella, A. B., Paixão, F. C., Migliavaca, A., Guimarães, J. R., Graudenz, M. S., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00712 · Cited by 23 · see citing works

Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease

Antonelli, A., Ferrari, S. M., Frascerra, S., Corrado, A., Pupilli, C., Bernini, G. P., Benvenga, S., Ferrannini, E., & Fallahi, P. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.04.007 · Cited by 23 · see citing works

CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo

Antonelli, A., Bocci, G., Motta, C. L., Ferrari, S. M., Fallahi, P., Corrado, A., Fioravanti, A., Sartini, S., Orlandi, P., Piaggi, S., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.06.002 · Cited by 22 · see citing works

Sorafenib in the treatment of thyroid cancer

Ferrari, S. M., Politti, U., Spisni, R., Materazzi, G., Baldini, E., Ulisse, S., Miccoli, P., Antonelli, A., & Fallahi, P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1064770 · Cited by 20 · see citing works

Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer

Ferrari, S. M., Motta, C. L., Sartini, S., Baldini, E., Materazzi, G., Politti, U., Ruffilli, I., Ulisse, S., Miccoli, P., Antonelli, A., et al. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151016124208 · Cited by 20 · see citing works

Molecular Diagnostics of Fine Needle Aspiration for the Presurgical Screening of Thyroid Nodules

Fallahi, P., Giannini, R., Miccoli, P., Antonelli, A., & Basolo, F. (2014) · Current Genomics · doi:10.2174/1389202915999140404100347 · Cited by 18 · see citing works

Nevirapine Increases Sodium/Iodide Symporter-Mediated Radioiodide Uptake by Activation of TSHR/cAMP/CREB/PAX8 Signaling Pathway in Dedifferentiated Thyroid Cancer

Shang, H., Zhao, J., Yao, J., Wang, H. J., Dong, J., & Liao, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00404 · Cited by 18 · see citing works

Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro

Ferrari, S. M., Fallahi, P., Motta, C. L., Bocci, G., Corrado, A., Materazzi, G., Galleri, D., Piaggi, S., Danesi, R., Settimo, F. D., et al. (2014) · Surgery · doi:10.1016/j.surg.2014.05.005 · Cited by 17 · see citing works

Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.

Sartini, S., Coviello, V., Bruno, A., Pietra, V. L., Marinelli, L., Simorini, F., Taliani, S., Salerno, S., Marini, A. M., Fioravanti, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401358b · Cited by 17 · see citing works

Advances in small molecule therapy for treating metastatic thyroid cancer

Krajewska, J., Gawlik, T., & Jarząb, B. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340939 · Cited by 17 · see citing works

Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors

Pietra, V. L., Sartini, S., Botta, L., Antonelli, A., Ferrari, S. M., Fallahi, P., Moriconi, A., Coviello, V., Quattrini, L., Ke, Y., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.080 · Cited by 17 · see citing works

Current progress in synthetic and medicinal chemistry of pyrazole hybrids as potent anticancer agents with SAR studies

Nehra, B., Kumar, M., Chawla, V., & Chawla, P. A. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00821-7 · Cited by 16 · see citing works

CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation

Fallahi, P., Ferrari, S. M., Motta, C. L., Materazzi, G., Bocci, G., Settimo, F. D., Miccoli, P., & Antonelli, A. (2015) · Endocrine · doi:10.1007/s12020-015-0717-4 · Cited by 16 · see citing works

Thyroid involvement in hepatitis C — Associated mixed cryoglobulinemia

Fallahi, P., Ferrari, S. M., Giuggioli, D., Manfredi, A., Mancusi, C., Fabiani, S., Centanni, M., Marchi, S., Ferri, C., & Antonelli, A. (2014) · HORMONES · doi:10.1007/bf03401317 · Cited by 15 · see citing works

The protective effect of myo-inositol on human thyrocytes

Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Caruso, C., Benvenga, S., Fallahi, P., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9476-x · Cited by 15 · see citing works

Personalization of Targeted Therapy in Advanced Thyroid Cancer

Fallahi, P., Ferrari, S. M., Mazzi, V., Vita, R., Benvenga, S., & Antonelli, A. (2014) · Current Genomics · doi:10.2174/1389202915999140404101902 · Cited by 13 · see citing works

Thyroid Cancer - Advances in Diagnosis and Therapy

Ahmadzadehfar, H. (2016) · InTech eBooks · doi:10.5772/61889 · Cited by 13 · see citing works

Metastatic Propagation of Thyroid Cancer; Organ Tropism and Major Modulators

Rajabi, S., Shakib, H., Dastmalchi, R., Daneshafrooz, A., Karima, S., & Hedayati, M. (2020) · Future Oncology · doi:10.2217/fon-2019-0780 · Cited by 12 · see citing works

Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro

Ferrari, S. M., Ragusa, F., Elia, G., Mazzi, V., Balestri, E., Botrini, C., Rugani, L., Patrizio, A., Piaggi, S., Motta, C. L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126734 · Cited by 11 · see citing works

Medical Therapy for Advanced Forms of Thyroid Cancer

Rajhbeharrysingh, U., Taylor, M. H., & Milas, M. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.03.003 · Cited by 11 · see citing works

Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy

Ferrari, S. M., Antonelli, A., Guidi, P., Bernardeschi, M., Scarcelli, V., Fallahi, P., & Frenzilli, G. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1604004 · Cited by 11 · see citing works

The Th1 chemokine IP-10 in Systemic sclerosis.

Corrado, A. (2014) · PubMed · doi:10.7417/ct.2014.1789 · Cited by 10 · see citing works

Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer

Miccoli, P. (2014) · Current Genomics · doi:10.2174/1389202915999140404101257 · Cited by 9 · see citing works

Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture

Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Patrizio, A., Piaggi, S., Baldini, E., Centanni, M., Motta, C. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032398 · Cited by 9 · see citing works

Proteomics, and Metabolomics: Magnetic Resonance Spectroscopy for the Presurgical Screening of Thyroid Nodules

Minuto, M. N., Shintu, L., & Caldarelli, S. (2014) · Current Genomics · doi:10.2174/1389202915999140404100701 · Cited by 9 · see citing works

Emerging Therapies in Sight for the Fight against Dedifferentiated Thyroid Cancer

Benvenga, S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2799 · Cited by 9 · see citing works

Sunitinib therapy in metastatic papillary thyroid cancer

Gori, S., Foglietta, J., Rossi, M., Hamzaj, A., Stocchi, L., Galuppo, C., Picece, V., Puxeddu, E., & Furlani, L. (2013) · Tumori Journal · doi:10.1177/030089161309900621 · Cited by 8 · see citing works

Targeted Treatment of Differentiated and Medullary Thyroid Cancer

Bales, S. R., & CHOPRA, I. J. (2011) · Journal of Thyroid Research · doi:10.4061/2011/102636 · Cited by 7 · see citing works

MIG in Crohn's disease.

Caruso, C. (2019) · PubMed · doi:10.7417/ct.2019.2134 · Cited by 7 · see citing works

CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide

Fallahi, P., Foddis, R., Elia, G., Ragusa, F., Patrizio, A., Benvenga, S., Cristaudo, A., Antonelli, A., & Ferrari, S. M. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9121 · Cited by 6 · see citing works

Low-grade endometrioid carcinoma of the ovary associated with undifferentiated carcinoma: case report and review of the literature.

Chen, L., Pang, S., Shen, Y., Liu, Z., Luan, J. Y., Shi, Y., & Liu, Y. (2014) · PubMed Central · Cited by 6 · see citing works

Synthesis, spectroscopic characterization, antimicrobial activity, and computational studies of five and/or six heterocyclic nitrogen rings linked to thienopyrazole moiety

Reheim, M. A. M. A., Hafiz, I. S. A., Reffat, H. M., Rady, H. S. A., & Abdelmonsef, A. H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140456 · Cited by 1 · see citing works

BindingDB Entry 50033953: Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.

BindingDB (2012) · UC San Diego · doi:10.7270/q29g5n6p

BindingDB Entry 50043948: Structure-based optimization of tyrosine kinase inhibitor CLM3. Design, synthesis, functional evaluation, and molecular modeling studies.

BindingDB (2014) · UC San Diego · doi:10.7270/q2x34zzp

BindingDB Entry 50002732: Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.

BindingDB (2020) · UC San Diego · doi:10.7270/q2b27xxb

In brief

(2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.8

A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer

ANTONELLI, A., BOCCI, G., Motta, C. L., Ferrari, S. M., Fallahi, P., Fioravanti, A., Stefania, S., DANESI, R., MICCOLI, P., Berti, P., et al. (n.d.) · CINECA IRIS Institutial research information system (University of Pisa)

CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo

Antonelli, A., Bocci, G., Fallahi, P., Motta, C. L., Ferrari, S. M., Mancusi, C., Fioravanti, A., Desidero, T. D., Sartini, S., Corti, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2321 · Cited by 51 · see citing works

The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro

Ferrari, S. M., Ragusa, F., Elia, G., Mazzi, V., Balestri, E., Botrini, C., Rugani, L., Piaggi, S., Motta, C. L., Antonelli, G., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04600-z

Effetto antitumorale di due nuovi inibitori della tirosina chinasi (CLM3 e CLM29) in cellule primarie di carcinoma dedifferenziato della tiroide

PACINI, E. (2011) · Electronic Theses and Dissertations Repository (University of Pisa)